In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lessons From The First Biosimilar MAb Launch In Europe

Executive Summary

Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.

Advertisement

Related Content

How US Can Learn From Biosimilar Implementation In EU
Biosimilars Education: Oncobiologics/Premier Deal Aims To Boost Adoption, Data Collection
Next Biosimilars Hurdle: Winning Over Physicians
Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
Remicade Patent Fails Reexamination After Mysterious Assault At PTO
Celltrion To Launch Biosimilar Remicade in More European Countries
Hospira Bulks Up Pfizer’s Established Products Unit, But Won’t Speed A Split
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel